Daniela Bota
Director, UC Irvine Alpha Stem Cell Clinic, Sue and Bill Gross Stem Cell Research Center · University of California
Credentials: · · · ·
History
- Present
UC Irvine Alpha Stem Cell Clinic · University of California
- Present
- 2003–2007
Neurology
Research
Lon protease preferentially degrades oxidized mitochondrial aconitase by an ATP-stimulated mechanism
Nature Cell Biology · 2002 · First of 2 authors · 471 citations
Journal of Translational Medicine · 2018 · 425 citations
JAMA Oncology · 2023 · 399 citations
- DA
11 papers · 11 as a resident
10 papers
- XK
8 papers
- BF
7 papers
7 papers · 5 as a fellow
7 papers
- DP
6 papers · 2 as a fellow
5 papers
Grants
- 2021–2027
Targeting p38/JNK MAPK to Ameliorate Cisplatin-Induced Adverse Sequelae on the Nervous System
National Cancer Institute · R01
Contact PI · $3.4M · University of California-Irvine
- 2020–2026
Targeting of Mitochondrial Lon Protease as a Novel Therapy for Glioblastoma
National Institute of Neurological Disorders and Stroke · R01
Contact PI · $2.3M · University of California-Irvine
- 2011–2017
Mechanisms of Chemotherapy Induced Cognitive Defects
National Institute of Neurological Disorders and Stroke · K08
Contact PI · $866.4K · University of California-Irvine
Clinical trials
- 2026–2027
Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT
Principal investigator · Recruiting · Phase 1, Phase 2
University of California, Irvine
- 2020–2025
Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma
Principal investigator · Completed
Daniela A. Bota
- 2019–2030
Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ
Principal investigator · Active not recruiting · Phase 2
University of California, Irvine
- 2014–2026
ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
Principal investigator · Unknown · Phase 2
Epitopoietic Research Corporation